The Effect of Dexmedetomidine for Suprascapular Nerve Block With Axillary Nerve Block

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-20

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Suprascapular nerve block (SSNB) is most commonly used for relieving postoperative pain of arthroscopic rotator cuff repair and it can be used in combination with axillary nerve block (ANB). Dexmedetomidine (DEX) is known as a type of alpha agonist which can elongate the duration of regional block. The aim of this study was to compare the results of dexmedetomidine combined with SSNB and ANB with SSNB and ANB alone on postoperative pain, satisfaction, and pain-related cytokines within the first 48 hours after arthroscopic rotator cuff repair.

Forty patients with rotator cuff tears who had undergone arthroscopic rotator cuff repair were enrolled in this single center, double-blinded randomized controlled trial study. Twenty patients were randomly allocated to group 1 and received ultrasound-guided SSNB and ANB using each mixture of 0.5 ml (50 μg) of DEX and 9.5 ml of 0.75% ropivacaine preemptively. The other 20 patients were allocated to group 2 and underwent ultrasound-guided SSNB and ANB alone using a mixture of 0.5 ml of normal saline and 9.5 ml of ropivacaine. The visual analog scale (VAS) for pain and patient satisfaction (SAT) scores were checked within 48 h postoperatively. The plasma interleukin (IL)-6, -8,-1β, cortisol, and serotonin levels were also measured within 48 h postoperatively.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexamethasone as an Adjuvant in Supraclavicular Block

NCT04345588

Dexamethasone Efficacy as an Adjuvant in Supraclavicular Block

UNKNOWN PHASE2

Dexmedetomidine Added to Ropivacaine Single Shot vs Continuous Interscalene Nerve Block

NCT05775861

Anesthesia Shoulder Pain Post Operative Pain

RECRUITING NA

Axillary Nerve Block Combined With Suprascapular Nerve Block

NCT02060812

Rotator Cuff Tear

COMPLETED NA

Low Dose Dexamethasone in Supraclavicular Blocks

NCT02666443

Rheumatoid Arthritis Osteoarthritis Nerve Entrapment +1 more

UNKNOWN NA

Different Doses of Intravenous Administered Dexamethasone Effecting Brachial Plexus Supraclavicular Block

NCT06389617

End Stage Renal Failure

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Suprascapular Nerve Block Axillary Nerve Block Dexmedetomidine Arthroscopic Rotator Cuff Repair Postoperative Pain Pain Related Cytokine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SSNB and ANB c DEX

We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for SSNB and ANB.

Group Type EXPERIMENTAL

Dexmedetomidine injection

Intervention Type DRUG

We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.

SSNB and ANB c saline

We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for SSNB and ANB.

Group Type PLACEBO_COMPARATOR

Saline injection

Intervention Type DRUG

We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine injection

We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.

Intervention Type DRUG

Saline injection

We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

suprascapular nerve block and axillary nerve block c ropivacaine arthroscopic rotator cuff repair suprascapular nerve block and axillary nerve block c ropivacaine arthroscopic rotator cuff repair

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* defined rotator cuff tear on preoperative MRI, which indicated repair
* acceptable arthroscopic surgery, including rotator cuff repair
* patients \>20 years old
* acceptable routine regional blocks and patient-controlled analgesia (PCA)

Exclusion Criteria

* did not undergo arthroscopic rotator cuff repair
* stopped PCA before 48 h postoperatively due to side effects
* had a concomitant operation for a Bankart lesion
* had a history of shoulder operation or fracture
* had a concomitant neurological disorder around the shoulder
* underwent conversion to open surgery from the arthroscopy
* had contraindications for the routine regional blocks used in this study
* had an known allergy or hypersensitivity against ropivacaine or dexmedetomidine, including other amino-amide local anesthetics or α2-adrenoceptor agonists.

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No